Detalles de la búsqueda
1.
Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
Diabetes Metab Res Rev
; 39(8): e3699, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37485788
2.
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
Diabetes Obes Metab
; 25(1): 198-207, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36089810
3.
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Cardiovasc Diabetol
; 21(1): 63, 2022 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35484607
4.
Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Diabetes Obes Metab
; 24(1): 115-124, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34580975
5.
Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function.
Am J Physiol Renal Physiol
; 320(6): F1152-F1158, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33900855
6.
Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross-sectional study.
Microcirculation
; 28(6): e12700, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33864418
7.
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Kidney Int
; 97(1): 202-212, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31791665
8.
Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Diabetes Obes Metab
; 22(10): 1847-1856, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32476255
9.
Renal sinus fat and renal hemodynamics: a cross-sectional analysis.
MAGMA
; 33(1): 73-80, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31471702
10.
Plasma uric acid and renal haemodynamics in type 2 diabetes patients.
Nephrology (Carlton)
; 25(4): 290-297, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31429150
11.
Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
Am J Physiol Renal Physiol
; 316(2): F231-F240, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353743
12.
Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance.
Microcirculation
; 26(7): e12580, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31313410
13.
Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Diabetes Obes Metab
; 20(5): 1235-1245, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29341461
14.
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
J Am Soc Nephrol
; 28(4): 1023-1039, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28143897
15.
Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Diabetes Obes Metab
; 19(12): 1669-1680, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449402
16.
GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Arterioscler Thromb Vasc Biol
; 36(10): 2125-32, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27562916
17.
Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study.
Scand J Gastroenterol
; 52(8): 881-885, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28446050
18.
GLP-1 based therapies: clinical implications for gastroenterologists.
Gut
; 65(4): 702-11, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26786687
19.
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Diabetologia
; 59(7): 1412-1421, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27038451
20.
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Diabetologia
; 59(12): 2588-2593, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27627981